Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Prudential Financial Inc.

Prudential Financial Inc. lifted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 100,538 shares of the biotechnology company's stock after acquiring an additional 10,687 shares during the quarter. Prudential Financial Inc. owned 0.16% of Blueprint Medicines worth $8,769,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of BPMC. Torray Investment Partners LLC grew its stake in Blueprint Medicines by 1.1% during the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock valued at $1,439,000 after purchasing an additional 186 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock worth $3,259,000 after buying an additional 265 shares in the last quarter. Hillsdale Investment Management Inc. increased its stake in shares of Blueprint Medicines by 0.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock worth $4,433,000 after buying an additional 310 shares during the last quarter. Quarry LP acquired a new stake in Blueprint Medicines in the third quarter valued at $32,000. Finally, Van ECK Associates Corp raised its holdings in Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $97,000 after acquiring an additional 363 shares in the last quarter.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BPMC shares. HC Wainwright reissued a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Wolfe Research began coverage on Blueprint Medicines in a report on Tuesday, March 18th. They set an "outperform" rating on the stock. Wedbush reiterated an "outperform" rating and issued a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Finally, Needham & Company LLC restated a "buy" rating and set a $133.00 price objective on shares of Blueprint Medicines in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $124.95.

Blueprint Medicines Stock Performance

BPMC traded down $2.57 during trading hours on Tuesday, hitting $85.94. The company's stock had a trading volume of 1,434,271 shares, compared to its average volume of 734,250. The company has a 50-day simple moving average of $97.70 and a 200 day simple moving average of $94.07. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $5.49 billion, a PE ratio of -79.57 and a beta of 0.58. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, sell-side analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insiders Place Their Bets

In related news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the transaction, the chief operating officer now directly owns 69,266 shares of the company's stock, valued at $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kate Haviland sold 1,446 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,608 shares of company stock worth $3,319,587. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.